XML 82 R67.htm IDEA: XBRL DOCUMENT
v3.25.0.1

COLLABORATIONS AND OTHER ARRANGEMENTS (Details) € in Millions, shares in Millions, $ in Millions |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 13, 2021 USD ($) | Jul. 13, 2020 USD ($) | May 27, 2020 | Jan. 31, 2025 USD ($) | Dec. 31, 2023 USD ($) | May 31, 2023 USD ($) | Apr. 30, 2022 USD ($) | Aug. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2024 USD ($) designee | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2014 | Jan. 31, 2025 EUR (€) | Jan. 31, 2024 USD ($) shares | Jan. 30, 2023 | Nov. 18, 2021 program | Oct. 23, 2020 USD ($) | Dec. 31, 2019 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  | $ 4,663 | $ 1,155 | $ 944 |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  | 5,907 | 5,718 | 4,977 |  |  |  |  |  |  |
Cost of goods sold |  |  |  |  |  |  |  |  |  | 6,251 | 6,498 | 5,657 |  |  |  |  |  |  |
Selling, general and administrative expenses |  |  |  |  |  |  |  |  |  | $ 6,091 | 6,090 | 5,673 |  |  |  |  |  |  |
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100 |  |  |  |
Additional equity investment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 320 |  |  |  |
Number of designees on board of directors | designee |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |
Arcus | Nonoperating Income (Expense) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 87 |  |  |  |
Arcus | Prepaid and other current assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity investment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 233 |  |  |  |
Galapagos |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of designees on board of directors | designee |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Abingworth |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential future milestone payments |  |  |  |  | $ 84 |  |  |  |  |  | 84 |  |  |  |  |  |  |  |
Funding received |  |  |  |  |  |  |  |  |  |  | 50 |  |  |  |  |  |  |  |
Funding expenses |  |  |  |  |  |  |  |  |  | $ 78 |  |  |  |  |  |  |  |  |
Abingworth | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding received |  |  |  |  | 210 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Abingworth |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment upon approval |  |  |  |  | 84 |  |  |  |  |  | 84 |  |  |  |  |  |  |  |
Dragonfly Therapeutics Collaboration Agreement | Dragonfly Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire in process research and development |  |  |  |  |  |  | $ 300 |  |  |  |  |  |  |  |  |  |  |  |
Additional payments to acquire in process research and development |  |  |  |  |  |  |  |  |  |  |  | 15 |  |  |  |  |  |  |
Merck Sharp & Dohme Corp |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global and development and commercialization costs | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues recognized |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |  |  |  |  |
Option period to license certain inhibitors (in years) | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |  |  |  |  |
Merck Sharp & Dohme Corp | Oral Formulation Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net product sales threshold | $ 2,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global product revenues | 65.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Sharp & Dohme Corp | Injectable Formulation Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net product sales threshold | $ 3,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global product revenues | 65.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Sharp & Dohme Corp | Merck |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global and development and commercialization costs | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen pharmaceuticals |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price of goods less specified amount, maximum percentage |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |  |  |  |  |
Cost of goods sold |  |  |  |  |  |  |  |  |  | 403 | 430 | 483 |  |  |  |  |  |  |
Period subject to termination (in years) |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |
Japan tobacco |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense |  |  |  |  |  |  |  |  |  | 139 | 167 | 198 |  |  |  |  |  |  |
Cash paid |  |  |  |  |  |  |  |  | $ 559 |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets acquired |  |  |  |  |  |  |  |  | $ 550 |  |  |  |  |  |  |  |  |  |
Amortization useful life (in years) |  |  |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |
Everest Medicines | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets acquired |  |  |  |  |  |  |  |  |  |  |  | 50 |  |  |  |  |  |  |
Finite-lived intangible asset |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 175 |
Selling, general and administrative expenses |  |  |  |  |  |  |  |  |  |  |  | 406 |  |  |  |  |  |  |
Everest Medicines | Everest Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential future milestone payments |  |  |  |  |  |  |  |  |  |  |  | 175 |  |  |  |  |  |  |
Upfront termination payments |  |  |  |  |  |  |  |  |  |  |  | 280 |  |  |  |  |  |  |
Termination payments |  |  |  |  |  |  |  |  |  |  | 196 | 84 |  |  |  |  |  |  |
LEO Pharma agreement | LEO Pharma A/S | Subsequent event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire in process research and development |  |  |  | $ 250 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional payments (up to) |  |  |  | $ 1,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arcellx, Inc | Global Strategic Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  | 68 | 313 |  |  |  |  |  |  |  |
Payments to acquire shares |  |  |  |  |  |  |  |  |  |  | 299 |  |  |  |  |  |  |  |
Percentage of profits earned |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |
Maximum potential future milestone payments |  |  |  |  | $ 1,500 |  |  |  |  |  | 1,500 |  |  |  |  |  |  |  |
Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of profits earned |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares owned (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.1 |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 33.00% |  |  |  |
Arcus | Arcus collaboration agreement and stock purchase agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Opt-in term (in years) |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of clinical stage programs with exercise options | program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Collaboration opt-in payments |  |  |  |  |  |  |  |  |  |  |  | 725 |  |  |  |  |  |  |
Arcus | Arcus collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential future milestone payments |  |  |  |  |  | $ 420 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, up-front fee paid |  |  |  |  |  | $ 35 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  | $ 243 | $ 189 | $ 187 |  |  |  |  |  |  |
Additional option fee in future years |  | $ 100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arcus | Arcus stock purchase agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum percentage of outstanding stock allowed to be purchased |  | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase period (in years) |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Galapagos | Galapagos subscription agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 25.80% |  |  |  |  |  |  |  |  |  |  |
Collaboration term (in years) |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Potential option exercise fee |  |  |  |  |  |  |  | $ 150 |  |  |  |  |  |  |  |  |  |  |
Payment of tiered royalties, low-end percentage |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |
Payment of tiered royalties, high-end percentage |  |  |  |  |  |  |  | 24.00% |  |  |  |  |  |  |  |  |  |  |
Maximum ownership percentage |  |  |  |  |  |  |  | 29.90% |  |  |  |  |  |  |  |  |  |  |
Shares of common stock acquired (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.7
Standstill restricting term (in years) |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Galapagos | Galapagos subscription agreement | Subsequent event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |
SpinCo | Galapagos subscription agreement | Subsequent event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |
Initial capital allocation (up to) |  |  |  | $ 2,540 |  |  |  |  |  |  |  |  |  | € 2,450 |  |  |  |  |

X
- Definition Collaboration Agreement, Up-front Fee Paid + References No definition available. + Details
Name: | gild_CollaborationAgreementUpFrontFeePaid
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period + References No definition available. + Details
Name: | gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Net Product Sales Threshold + References No definition available. + Details
Name: | gild_CollaborationArrangementNetProductSalesThreshold
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Arrangement, Percent Of Global Development And Commercialization Costs + References No definition available. + Details
Name: | gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Percent Of Global Product Revenues + References No definition available. + Details
Name: | gild_CollaborationArrangementPercentOfGlobalProductRevenues
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Opt-In Term + References No definition available. + Details
Name: | gild_CollaborativeAgreementOptInTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Product Market Period Subject To Termination + References No definition available. + Details
Name: | gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Initial Capital Allocation Upon Separation + References No definition available. + Details
Name: | gild_CollaborativeArrangementInitialCapitalAllocationUponSeparation
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Additional Payments + References No definition available. + Details
Name: | gild_CollaborativeArrangementRightsAndObligationsAdditionalPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Term + References No definition available. + Details
Name: | gild_CollaborativeArrangementTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Method Investment, Additional Investment + References No definition available. + Details
Name: | gild_EquityMethodInvestmentAdditionalInvestment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Method Investment, Option Fee + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionFee
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Method Investment, Ownership Interest, Shares + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOwnershipInterestShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Additional Option Fee On Future Anniversaries + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFutureAnniversaries
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Purchase Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial consideration for acquisition of rights to market and distribute certain products in Japan + References No definition available. + Details
Name: | gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement + References No definition available. + Details
Name: | gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Clinical Stage Programs With Exercised Options + References No definition available. + Details
Name: | gild_NumberOfClinicalStageProgramsWithExercisedOptions
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Designees On Board Of Directors + References No definition available. + Details
Name: | gild_NumberOfDesigneesOnBoardOfDirectors
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments To Acquire Additional In Process Research And Development + References No definition available. + Details
Name: | gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Opt-In The Collaborative Agreement + References No definition available. + Details
Name: | gild_PaymentsToOptInTheCollaborativeAgreement
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Terminate Previous Agreement + References No definition available. + Details
Name: | gild_PaymentsToTerminatePreviousAgreement
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Future Milestone Payments, Maximum + References No definition available. + Details
Name: | gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Option Exercise Fee Per Program + References No definition available. + Details
Name: | gild_PotentialOptionExerciseFeePerProgram
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Sales Based Tiered Royalties High-end, Percentage + References No definition available. + Details
Name: | gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Sales Based Tiered Royalty, Low-end, Percentage + References No definition available. + Details
Name: | gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase Price Of Goods Less Specified Amount, Maximum Percentage + References No definition available. + Details
Name: | gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Performance Obligation, Percentage Of U.S. Profits + References No definition available. + Details
Name: | gild_RevenuePerformanceObligationPercentageOfUSProfits
Namespace Prefix: | gild_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount Upon Approval + References No definition available. + Details
Name: | gild_RevenueRemainingPerformanceObligationVariableConsiderationAmountUponApproval
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Standstill Restricting Term + References No definition available. + Details
Name: | gild_StandstillRestrictingTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Payments To Terminate Previous Agreement + References No definition available. + Details
Name: | gild_UpfrontPaymentsToTerminatePreviousAgreement
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of investment owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_NonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_GalapagosNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_AbingworthLLPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_AbingworthLLPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_DragonflyTherapeuticsCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OralFormulationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_EverestMedicinesAndImmunomedicsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_EverestMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_LEOPharmaASAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_LEOPharmaASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_SpinCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |